Source: South West Medicines Information and Training
Area: Evidence > Drug Specific Reviews
Fentanyl nasal spray (Instanyl®) is licensed for breakthrough pain in adults receiving maintenance opioid therapy for chronic cancer pain. There are several other immediate release fentanyl products already on the market for this indication. Instanyl® is the first intranasal formulation available. There are two published randomised controlled trials of Instanyl®. Its use resulted in significantly superior pain reduction at 10 minutes compared to placebo, and provided analgesia around 5 minutes faster than oral transmucosal fentanyl (Actiq®).
The safety profile of Instanyl® appears comparable to that of other fentanyl containing products indicated in the treatment of breakthrough cancer pa…
Source: MedWorm: Oral Cancer